Sanofi Sarclisa accepted for USFDA priority review for transplant-ineligible newly diagnosed multiple myeloma Ruchika Sharma27 May 2024 11:30 AM ISTParis: Sanofi has announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License...
Dr Reddy's Labs expects strong product pipeline in North America for FY25 Ruchika Sharma9 May 2024 5:47 PM ISTBengaluru: Dr. Reddy's Laboratories, based in India, forecasts a strong product lineup for its key market in North America in the fiscal year...
Dr.Reddy's Labs gets CDSCO Panel Nod To Manufacture, Market anti-cancer drug Lenalidomide 20mg additional strength Dr. Divya Colin19 April 2024 6:00 PM ISTNew Delhi: The drug major Dr Reddy's Labs has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Sarclisa plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone: Sanofi Ruchika Sharma11 Dec 2023 2:30 PM ISTParis: Sanofi has announced that the Phase 3 trial investigating Sarclisa (isatuximab) in combination with carfilzomib, lenalidomide and...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
Dr Reddy's Gets CDSCO Panel Nod to Manufacture, Market Anticancer Drug Lenalidomide Capsules Dr. Divya Colin26 May 2023 6:00 PM ISTNew Delhi: In a significant development, the drug major Dr. Reddy's Laboratories has got a green signal from the Subject Expert Committee (SEC)...
Cipla Cancer drug Lenalidomide bags USFDA okay Ruchika Sharma7 Sept 2022 4:22 PM ISTMumbai: Drugmaker, Cipla Limited, today announced that the company has received final approval for its Abbreviated New Drug Application (ANDA) for...
Pfizer, MorphoSys and Incyte enter trial collaboration for Monjuvi in combination with TTI-622 Ruchika Sharma15 Jun 2022 10:00 AM ISTUnder the terms of the agreement, Pfizer will initiate a multicenter, international Phase 1b/2 study of TTI-622 with Monjuvi and lenalidomide for...
NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market MD Bureau8 March 2022 2:50 PM ISTNATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene.
Sandoz unveils generic oncology medicine Lenalidomide in Europe Ruchika Sharma19 Feb 2022 11:37 AM ISTBasel: Sandoz has recently announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as...
Biocon, Celgene settle patent litigation over cancer drug Revlimid Ruchika Sharma9 Sept 2021 2:58 PM ISTNew Delhi: Biotechnology major Biocon on Wednesday said it has entered into a settlement with Celgene Corporation regarding patents for Revlimid, a...
Dr Reddys launches Reddy-Lenalidomide in Canada Ruchika Sharma3 Sept 2021 12:45 PM ISTHyderabad: Drugmaker, Dr. Reddy's Laboratories Ltd., has recently announced that Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide)...
